A nomogram based on LI-RADS features, clinical indicators and quantitative contrast-enhanced MRI parameters for predicting glypican-3 expression in hepatocellular carcinoma

Frontiers in Oncology

Oncology

Xue-wu Zhang¹  Tong Chen²  Xu-jun Qian²  Zhi Zhu²  Yue-yue Zhang²  Chao-gang Wei²  Rui Zhang²  Wei Hu²  Qin Yu³  Yan Song⁴  Jun-kang Shen⁵ 

[1] Department of Infectious Diseases, Jieshou City People’s Hospital, Fuyang, China;Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China;Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China;Department of Radiology, Dongtai City People’s Hospital, Yancheng, China;Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China;Department of Radiology, Jieshou City People’s Hospital, Fuyang, China;Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China;Institute of Imaging Medicine, Soochow University, Suzhou, China;

关键词: hepatocellular carcinoma;    glypican-3;    immunotherapy;    LI-RADS;    Gd-EOB-DTPA;    nomogram;   

DOI  :  10.3389/fonc.2023.1123141

 received in 2022-12-13, accepted in 2023-01-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

PurposeNoninvasively assessing the tumor biology and microenvironment before treatment is greatly important, and glypican-3 (GPC-3) is a new-generation immunotherapy target for hepatocellular carcinoma (HCC). This study investigated the application value of a nomogram based on LI-RADS features, quantitative contrast-enhanced MRI parameters and clinical indicators in the noninvasive preoperative prediction of GPC-3 expression in HCC.Methods and materialsWe retrospectively reviewed 127 patients with pathologically confirmed solitary HCC who underwent Gd-EOB-DTPA MRI examinations and related laboratory tests. Quantitative contrast-enhanced MRI parameters and clinical indicators were collected by an abdominal radiologist, and LI-RADS features were independently assessed and recorded by three trained intermediate- and senior-level radiologists. The pathological and immunohistochemical results of HCC were determined by two senior pathologists. All patients were divided into a training cohort (88 cases) and validation cohort (39 cases). Univariate analysis and multivariate logistic regression were performed to identify independent predictors of GPC-3 expression in HCC, and a nomogram model was established in the training cohort. The performance of the nomogram was assessed by the area under the receiver operating characteristic curve (AUC) and the calibration curve in the training cohort and validation cohort, respectively.ResultsBlood products in mass, nodule-in-nodule architecture, mosaic architecture, contrast enhancement ratio (CER), transition phase lesion-liver parenchyma signal ratio (TP-LNR), and serum ferritin (Fer) were independent predictors of GPC-3 expression, with odds ratios (ORs) of 5.437, 10.682, 5.477, 11.788, 0.028, and 1.005, respectively. Nomogram based on LI-RADS features (blood products in mass, nodule-in-nodule architecture and mosaic architecture), quantitative contrast-enhanced MRI parameters (CER and TP-LNR) and clinical indicators (Fer) for predicting GPC-3 expression in HCC was established successfully. The nomogram showed good discrimination (AUC of 0.925 in the training cohort and 0.908 in the validation cohort) and favorable calibration. The diagnostic sensitivity and specificity were 76.9% and 92.3% in the training cohort, 76.8% and 93.8% in the validation cohort respectively.ConclusionThe nomogram constructed from LI-RADS features, quantitative contrast-enhanced MRI parameters and clinical indicators has high application value, can accurately predict GPC-3 expression in HCC and may help noninvasively identify potential patients for GPC-3 immunotherapy.

【 授权许可】

Unknown   
Copyright © 2023 Song, Zhang, Yu, Chen, Wei, Zhang, Hu, Qian, Zhu, Zhang and Shen